Table 1.
Characteristic | Nevirapine Group | Ritonavir-Boosted Lopinavir Group | Total Cohort | ||||
---|---|---|---|---|---|---|---|
Children <12 mo (N = 60) | Children ≥12 mo (N = 22) | All Children (N = 82) | Children <12 mo (N = 63) | Children ≥12 mo (N = 19) | All Children (N = 82) | Total (N = 164) | |
Age — yr | |||||||
Median | 0.6 | 1.5 | 0.7 | 0.6 | 1.5 | 0.7 | 0.7 |
10th–90th percentile | 0.5 to 0.9 | 1.1 to 2.2 | 0.5 to 1.6 | 0.5 to 0.8 | 1.2 to 2.6 | 0.5 to 1.7 | 0.5 to 1.7 |
Weight z score | |||||||
Median | −1.2 | −1.5 | −1.3 | −0.9 | −1.1 | −1.1 | −1.1 |
10th–90th percentile | −3.2 to 0.8 | −5.5 to −0.2 | −3.7 to 0.5 | −2.6 to 0.5 | −3.4 to 0.2 | −2.7 to 0.4 | −3.3 to 0.4 |
Height z score | |||||||
Median | −1.3 | −1.8 | −1.5 | −0.9 | −1.3 | −1.0 | −1.2 |
10th–90th percentile | −3.1 to 0.3 | −3.1 to −0.2 | −3.1 to 0.2 | −2.5 to 0.4 | −2.8 to 0.1 | −2.5 to 0.1 | −2.7 to 0.2 |
Percentage of CD4+ lymphocytes | |||||||
Median | 19.2 | 16.9 | 18.9 | 21.1 | 15.2 | 19.7 | 19.0 |
10th–90th percentile | 12.0 to 31.4 | 9.8 to 27.1 | 10.5 to 30.7 | 14.0 to 30.6 | 7.3 to 33.0 | 9.7 to 30.6 | 10.4 to 30.7 |
HIV-1 RNA — log10 copies/ml† | |||||||
Median | 5.9 | 5.9 | 5.9 | 5.9 | 5.9 | 5.9 | 5.9 |
10th–90th percentile | 5.1 to 5.9 | 5.4 to 5.9 | 5.2 to 5.9 | 5.2 to 5.9 | 5.4 to 5.9 | 5.2 to 5.9 | 5.2 to 5.9 |
Male sex — no. (%) | 28 (46.7) | 8 (36.4) | 36 (43.9) | 31 (49.2) | 10 (52.6) | 41 (50.0) | 77 (47.0) |
Breast-fed — no. (%) | 13 (21.7) | 2 (9.1) | 15 (18.3) | 18 (28.6) | 1 (5.3) | 19 (23.2) | 34 (20.7) |
WHO disease stage — no. (%) | |||||||
1 | 5 (8.3) | 0 | 5 (6.1) | 16 (25.4) | 3 (15.8) | 19 (23.2) | 24 (14.6) |
2 | 23 (38.3) | 3 (13.6) | 26 (31.7) | 19 (30.2) | 3 (15.8) | 22 (26.8) | 48 (29.3) |
3 | 27 (45.0) | 11 (50.0) | 38 (46.3) | 25 (39.7) | 12 (63.2) | 37 (45.1) | 75 (45.7) |
4 | 5 (8.3) | 8 (36.4) | 13 (15.9) | 3 (4.8) | 1 (5.3) | 4 (4.9) | 17 (10.4) |
WHO denotes World Health Organization.
HIV-1 RNA levels were censored at the upper limit of the assay (5.9 log10 copies per milliliter).